enGene (NASDAQ:ENGN) Now Covered by Piper Sandler

Piper Sandler assumed coverage on shares of enGene (NASDAQ:ENGN) in a report released on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $26.00 price target on the stock.

A number of other research analysts have also recently commented on ENGN. HC Wainwright started coverage on enGene in a research report on Monday, December 23rd. They issued a “buy” rating and a $25.00 price target on the stock. Raymond James began coverage on shares of enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price for the company. JMP Securities reiterated a “market outperform” rating and set a $18.00 price target on shares of enGene in a research report on Monday, December 23rd. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research note on Monday, November 18th. Finally, UBS Group cut enGene from a “buy” rating to a “neutral” rating and cut their target price for the stock from $34.00 to $7.00 in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $26.40.

enGene Trading Up 2.1 %

Shares of NASDAQ:ENGN opened at $6.03 on Tuesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The company has a 50-day simple moving average of $6.83 and a 200 day simple moving average of $7.23. The company has a market capitalization of $266.43 million, a P/E ratio of -10.39 and a beta of -0.65. enGene has a 52-week low of $4.42 and a 52-week high of $18.40.

enGene (NASDAQ:ENGN) last announced its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. Sell-side analysts forecast that enGene will post -1.57 earnings per share for the current year.

Institutional Trading of enGene

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wolverine Asset Management LLC acquired a new stake in enGene during the 3rd quarter worth approximately $37,000. Vontobel Holding Ltd. acquired a new position in shares of enGene during the fourth quarter worth $69,000. Jane Street Group LLC acquired a new position in shares of enGene during the fourth quarter worth $93,000. Toronto Dominion Bank bought a new stake in shares of enGene in the fourth quarter worth $97,000. Finally, Cubist Systematic Strategies LLC increased its holdings in enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock valued at $102,000 after purchasing an additional 2,080 shares during the period. 64.16% of the stock is currently owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.